PSMA-617 Inhibits Proliferation and Potentiates the Lu-PSMA-617-induced Death of Human Prostate Cancer Cells

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2023 Jun 7

PMID 37284895

Authors

Yi Zhao

Juraj Culman

Ingolf Cascorbi

Niklas Nithack

Marlies Marx

Maaz Zuhayra

Ulf Lutzen

Affiliations

Soon will be listed here.

Abstract

The human prostate-specific membrane antigen (PSMA) is substantially up-regulated in metastatic prostate cancer (PCa) cells. PSMA can be targeted by Lu conjugated to PSMA-617, a high-affinity ligand for the PSMA. The binding of the radioligand, Lu-PSMA-617, results in its internalisation and delivery of β-radiation into the cancer cells. However, PSMA-617, a component of the final product in the synthesis of the radioligand, may also play a role in the pathophysiology of PCa cells. The present study aimed to clarify the effects of PSMA-617 (10, 50 and 100 nM) on the expression of PSMA in PSMA-positive LNCaP cells, their proliferation, Lu-PSMA-617-induced cell death by WST-1 and lactate dehydrogenase assays, immunohistochemistry, western blotting, immunofluorescence staining and uptake of Lu-PSMA-617. PSMA-617 at 100 nM concentration induced cell-growth arrest, down-regulated cyclin D1 and cyclin E1 (by 43 and 36%, respectively) and up-regulated the cyclin-dependent kinase inhibitor p21 (by 48%). Immunofluorescence staining demonstrated reduced content of DNA, pointing to a lower rate of cell division. PSMA-617 (up to 100 nM) did not alter the uptake of Lu-PSMA-617 into the LNCaP cells. Interestingly, simultaneous treatment with Lu-PSMA-617 and PSMA-617 for 24 and 48 h substantially potentiated the cell-death promoting effects of the radioligand. In conclusion, the combination of impeding tumour cell proliferation by PSMA-617 and its potentiation of the radiation-induced cell death brought about by Lu-PSMA-617 in PCa cells may considerably improve the outcome of the radiation therapy with Lu-PSMA-617, especially in patients with decreased radiosensitivity of PCa cells to the radioligand.

References

Abbas T, Dutta A . p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009; 9(6):400-14. PMC: 2722839. DOI: 10.1038/nrc2657. View

Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E . Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015; 5(1):114. PMC: 4477007. DOI: 10.1186/s13550-015-0114-2. View

Baretton G, Klenk U, Diebold J, Schmeller N, Lohrs U . Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer. 1999; 80(3-4):546-55. PMC: 2362324. DOI: 10.1038/sj.bjc.6690390. View

Benesova M, Bauder-Wust U, Schafer M, Klika K, Mier W, Haberkorn U . Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J Med Chem. 2016; 59(5):1761-75. DOI: 10.1021/acs.jmedchem.5b01210. View

Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W . Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015; 56(6):914-20. DOI: 10.2967/jnumed.114.147413. View

Caromile L, Shapiro L . PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression. Mol Cell Oncol. 2017; 4(4):e1321168. PMC: 5540209. DOI: 10.1080/23723556.2017.1321168. View

El Fakiri M, Geis N, Ayada N, Eder M, Eder A . PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. Cancers (Basel). 2021; 13(16). PMC: 8393521. DOI: 10.3390/cancers13163967. View

Ghosh A, Heston W . Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004; 91(3):528-39. DOI: 10.1002/jcb.10661. View

Gillings N, Todde S, Behe M, Decristoforo C, Elsinga P, Ferrari V . EANM guideline on the validation of analytical methods for radiopharmaceuticals. EJNMMI Radiopharm Chem. 2020; 5(1):7. PMC: 7016057. DOI: 10.1186/s41181-019-0086-z. View

10.

Hernandez-Jimenez T, Cruz-Nova P, Ancira-Cortez A, Gibbens-Bandala B, Lara-Almazan N, Ocampo-Garcia B . Toxicity Assessment of [Lu]Lu-iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes. Nanomaterials (Basel). 2022; 12(23). PMC: 9739705. DOI: 10.3390/nano12234181. View

11.

Hong X, Mao L, Xu L, Hu Q, Jia R . Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes. Bioengineered. 2022; 13(1):995-1012. PMC: 8805960. DOI: 10.1080/21655979.2021.2016086. View

12.

Hwang H, Clurman B . Cyclin E in normal and neoplastic cell cycles. Oncogene. 2005; 24(17):2776-86. DOI: 10.1038/sj.onc.1208613. View

13.

Jang A, Kendi A, Sartor O . Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023; 15:17588359231157632. PMC: 9989419. DOI: 10.1177/17588359231157632. View

14.

Ju X, Casimiro M, Gormley M, Meng H, Jiao X, Katiyar S . Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Res. 2013; 74(2):508-19. PMC: 3914674. DOI: 10.1158/0008-5472.CAN-13-1313. View

15.

Kozikowski A, Nan F, Conti P, Zhang J, Ramadan E, Bzdega T . Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001; 44(3):298-301. DOI: 10.1021/jm000406m. View

16.

Kratochwil C, Giesel F, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A . PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016; 57(8):1170-6. DOI: 10.2967/jnumed.115.171397. View

17.

Lee J, Lehmann B, Terrian D, Chappell W, Stivala F, Libra M . Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle. 2008; 7(12):1745-62. PMC: 2593475. DOI: 10.4161/cc.7.12.6166. View

18.

Machulkin A, Uspenskaya A, Zyk N, Nimenko E, Ber A, Petrov S . PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation. Eur J Med Chem. 2021; 227:113936. DOI: 10.1016/j.ejmech.2021.113936. View

19.

Malumbres M, Barbacid M . To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2002; 1(3):222-31. DOI: 10.1038/35106065. View

20.

Matthias J, Engelhardt J, Schafer M, Bauder-Wust U, Meyer P, Haberkorn U . Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. Cancer Res. 2021; 81(8):2234-2245. DOI: 10.1158/0008-5472.CAN-20-1624. View